Kenneth Hoberman

Chief Operating Officer, STEMLINE THERAPEUTICS INC.

Companies

Nuvectis Pharma, Inc.Board member Feb 8, 2022 to now¹
TG TherapeuticsBoard member Dec 23, 2014 to now²

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

TG Therapeutics TGTX279,653 shares³$14.9M at $53.45Jun 12, 2025
Nuvectis Pharma, Inc. NVCT168,140 shares⁴$3.1M at $18.67Jun 11, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

Jun 11, 2026Granted 35,000 shares of Nuvectis Pharma, Inc.⁴
Jun 12, 2025Granted 14,718 shares of TG Therapeutics³
Jun 12, 2025Granted 30,000 shares of Nuvectis Pharma, Inc.⁵
Jun 19, 2024Granted 22,250 shares of TG Therapeutics⁶
Jun 13, 2024Granted 30,000 shares of Nuvectis Pharma, Inc.⁷
Sep 28, 2023Granted 20,000 shares of TG Therapeutics⁸
Jun 16, 2023Granted 18,000 shares of Nuvectis Pharma, Inc.⁹
Jul 20, 2022Granted 43,732 shares of TG Therapeutics¹⁰
May 12, 2022Bought 6,000 shares at $17.40 of Nuvectis Pharma, Inc.¹¹

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARNuvectis Pharma, Inc., Board member
2
SEC EDGARTG Therapeutics, Board member
3
SEC EDGARTG Therapeutics shares after the filing of Jun 12, 2025
4
SEC EDGARNuvectis Pharma, Inc. shares after the filing of Jun 11, 2026
5
SEC EDGARForm 4 filed Jun 12, 2025
6
SEC EDGARForm 4 filed Jun 20, 2024
7
SEC EDGARForm 4 filed Jun 13, 2024
8
SEC EDGARForm 4 filed Sep 29, 2023
9
SEC EDGARForm 4 filed Jun 20, 2023
10
SEC EDGARForm 4 filed Jul 22, 2022
11
SEC EDGARForm 4 filed May 16, 2022